Objective
Lung cancer is the leading cause of death by cancer in Europe. Non-small cell lung cancer (NSCLC) represents about 80% of total lung cancers. KRAS is the most commonly mutated oncogene in NSCLC, found in over 20% of patients. Since KRAS mutations are directly responsible for NSCLC, KRAS represents a relevant target to prevent NSCLC development. Yet, efforts to develop therapeutic inhibitors have failed for over 20 years, what represents an unmet clinical need in NSCLC. Thus, it is critical to identify targets of oncogenic KRAS that could unveil novel therapeutic candidates.
In preliminary studies, molecular screening of downstream effectors of activated KRAS led to identification of several microRNAs. MiR-181a and b (miR-181a/b) were among the top microRNAs up-regulated upon KRAS activation. Moreover, genetic deletion of the miR-181ab1 cluster significantly impaired lung tumor development in vivo. These preliminary findings suggest a prominent role for miR-181a/b in KRAS oncogenesis. Thus, this proposal aims to dissect the role of miR-181a/b in the context of mutant KRAS to identify downstream target genes required for KRAS oncogenesis.
We propose the following objectives:
1. To investigate the role of miR-181ab-1 cluster in vivo and the potential therapeutic value of miR-181a and b using a genetically-modified mouse model of Kras-driven NSCLC.
2. To uncover the functional role of miR-181a/b in human KRAS-driven oncogenesis using NSCLC cell lines and primary lung epithelial cells.
3. To identify miR-181a/b-regulated genes functionally critical for KRAS-dependent NSCLC.
4. To characterize the clinical implication of miR-181a/b-regulated genes in human NSCLC: translating in vitro and in vivo findings to human patients.
We believe that results from this proposal will expand our current knowledge of the signaling network regulated by mutant KRAS. We hope to apply these findings to develop innovative therapeutic strategies for NSCLC patients harboring KRAS mutations
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology lung cancer
- natural sciences biological sciences genetics mutation
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2013-CIG
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MC-CIG - Support for training and career development of researcher (CIG)
Coordinator
31008 Pamplona
Spain
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.